Abstract: Extracorporeal blood treatment is performed daily on a large number of patients by use of for example a dialysis filter, plasma filter or a centrifuge. The purpose of the treatment is to separate minor components and molecules in a liquid or in the blood from larger ones, for example in connection with different disease conditions or with a view to extracting blood plasma, target substances such as blood components or molecules from for example blood donors. According to the present invention two separation steps are used together with a solution or a suspension containing at least one component, which specifically may bind to the component or the blood component to be specifically reduced, or to be refined/extracted during the treatment or during the blood treatment.

Abstract: A Product is described and which contains at least one type of ligand bound to a separation material and which allows selective binding or cleavage of a biomolecule for example in human blood.

Abstract: A Product is described and which contains at least one type of ligand bound to a separation material and which allows selective binding or cleavage of a biomolecule for example in human blood.

Abstract: A Product is described and which contains at least one type of ligand bound to a separation material and which allows selective binding or cleavage of a biomolecule for example in human blood.

Abstract: Extracorporeal blood treatment is performed daily on a large number of patients by use of for example a dialysis filter, plasma filter or a centrifuge. The purpose of the treatment is to separate minor components and molecules in a liquid or in the blood from larger ones, for example in connection with different disease conditions or with a view to extracting blood plasma, target substances such as blood components or molecules from for example blood donors. According to the present invention two separation steps are used together with a solution or a suspension containing at least one component, which specifically may bind to the component or the blood component to be specifically reduced, or to be refined/extracted during the treatment or during the blood treatment.

Abstract: A Product is described and which contains at least one type of ligand bound to a separation material and which allows selective binding or cleavage of a biomolecule for example in human blood.

Abstract: Bio-affinity material containing at least one biologically active saccharide which is covalently bound via at least one spacer to a cross-linked matrix and that the material is autoclaved. Apparatus for contacting body fluids with the bio-affinity material is disclosed.

Abstract: Bio-affinity material containing at least one biologically active saccharide which is covalently bound via at least one spacer to a cross-linked matrix and that the material is autoclaved. Apparatus for contacting body fluids with the bio-affinity material is disclosed.

Abstract: Synthesis of an amino-disaccharide, amino-oligosaccharide or a derivative thereof, characterized in that a monosaccharide, a disaccharide, an oligosaccharide, a glycoside or a derivative thereof, in the presence of a glycosidase as catalyst, is reacted with an amino-deoxy-saccharide or a glycoside or derivative thereof, and that the amino-saccharide is optionally isolated from the product mixture directly or after chemical/enzymatic modification.

Abstract: Disclosed is a method of producing a compound which contains the Glc.beta.1-4GlcN structure involving reacting at least one donor substance Glc.beta.OR where R is an organic group, and at least one acceptor substance which is a glucopyranosamino derivative having the formula GlcNR"-R'", wherein NR" is an azido, 2-N-acetyl-, 2-N-phtalimido, or an organic group bound to the 2-N-group of glucosamine, wherein R'" is a glycosidically bound fluoro or is an O-, C-, N- or S-glycosidically bound aliphatic or aromatic compound, with the optional proviso that if NR" is NHAc then R'" is not OH and if NR" is not NHAc then R'" may be OH, in the presence of Bullera singularis or an E.C. group 3.2 glycosidase of essentially the same structure as an E.C. group 3.2 glucosidase obtained from Bullera singularis to form the Glc.beta.1-4GlcN derivative; and optionally isolating the compound which contains the Glc.beta.1-4GlcN structure.

Abstract: Synthesis of an amino-disaccharide, amino-oligosaccharide or a derivative thereof, characterized in that a monosaccharide, a disaccharide, an oligosaccharide, a glycoside or a derivative thereof, in the presence of a glycosidase as catalyst, is reacted with an amino-deoxy-saccharide or a derivative thereof, and that the amino-saccharide is isolated from the product mixture directly or after chemical/enzymatic modification.

Abstract: Synthesis of an amino-disaccharide, amino-oligosaccharide or a derivative thereof, characterized in that a monosaccharide, a disaccharide, an oligosaccharide, a glycoside or a derivative thereof, in the presence of a glycosidase as catalyst, is reacted with an amino-deoxy-saccharide or a derivative thereof, and that the amino-saccharide is isolated from the product mixture directly or after chemical/enzymatic modification.

Abstract: The invention relates to a reagent consisting of at least one enzyme and at least one other substance, which are covalently or noncovalently bound to a particle, which is smaller than or is equal to 1000 Angstrom in diameter. The invention also relates to method and use of the reagent for determination or studies of a cell or a virus or another component in a sample. According to the invention, these determinations are made with for example some ELISA-technique (competitive, sandwich, etc.), employing the reagent preferrably in the form of a suspension in buffered water, instead of and in the same way as described for soluble enzyme conjugates. The substance can be an antibody, a lectin, avidin or an antigen, the enzyme can be for example peroxidase, alkaline phosphatase, and the particle can be an inorganic or an organic polymeric compound or a combination thereof, as, for example, tresyl-activated glycerylpropyl-silica.

Abstract: Oligosaccharide compounds GlcNAc.beta.1-3Gal.beta.-OMe, GlcNAc.beta.1- 6Gal.alpha.-OMe, GalNAc.beta.1-3Gal.beta.-OMe, GalNAc.alpha.1-3Gal.alpha.-OMe, and Fuc.alpha.1-6Gal.beta.-OMe.

Abstract: The invention relates to a reagent consisting of at least one enzyme and at least one other substance, which are covalently or noncovalently bound to a particle, which is smaller than or is equal to 1000 Angstrom in diameter. The invention also relates to method and use of the reagent for determination or studies of a cell or a virus or another component in a sample. According to the invention, these determinations are made with for example some ELISA-technique (competitive, sandwich, etc), employing the reagent preferably in the form of a suspension in buffered water, instead of and in the same way as described for soluble enzyme conjugates. The substance can be antibody, a lectin, avidin or an antigen, the enzyme can be for example peroxidase, alcaline phosphatase, and the particle can be an inorganic or an organic polymeric compound or a combination thereof, as, for example, tresyl-activated glycerylpropyl-silica.

Abstract: A method of producing an oligosaccharide compound which either consists of or is a fragment or analog of the carbohydrate part in a glycoconjugate is disclosed which involves reacting(a) at least one oligosaccharide, disaccharide, monosaccharide, or glycoside as donor substance,(b) at least one acceptor substance containing a monosaccharide, disaccharide, oligosaccharide, glycoside, or saccharide analog, and(c) at least one enzyme composition produced from a mollusc and containing E.C. group 3.2 glycosidase, or the glycosidase is at least one glycosidase which has been cloned with recombinant technique and which has at least 70% homology in its amino acid sequence with the corresponding mollusc enzyme, to form the oligosaccharide compound;wherein the oligosaccharide compound contains(i) GlcNAc.beta.1-3Gal.beta. and the glycosidase is N-acetyl-.beta.-D-glucosaminidase,(ii) GlcNAc.beta.1-6Man.alpha. and the glycosidase is N-acetyl-.beta.-D-glucosaminidase,(iii) GlcNAc.beta.1-6Gal.alpha.

Abstract: A method for synthesis of oligosaccharide compounds which either consist of or are fragments or analogs of the carbohydrate part in glycoconjugates is described. The synthesis from donor and acceptor substrates is carried out in that at least one glycosidase and at least one glycosyltransferase are used as catalysts and the oligosaccharide compound is isolated from the reaction mixture.

Abstract: A method of controlling the regioselectivity of the glycosidic bond between glycosyl donor and glycosyl acceptor in the enzymatic production of an oligosaccharide compound which either consists of or is a fragment or an analog of the cabohydrate part in a glycoconjugate, by reverse hydrolysis or transglycosidation reactions, is described. The synthesis is carried out in that a donor substance which is a mono- or oligosaccharide or a glycoside thereof, is caused to react, in the presence of a glycosidase, with an acceptor substance which is an O-, N-, C- or S-glycoside consisting of a monosaccharide, oligosaccharide or a saccharide analog and at least one aglycon which is O-, N-, C- or S-glycosidically bonded in 1-position, the .alpha. or .beta.-configuration being selected on the glycoside bond between the glycosyl group and the aglycon in the acceptor substance, and the oligosaccharide compound being separated from the reaction mixture.

Abstract: The invention relates to a method of coupling organic ligands to a polymeric carrier. The organic ligand contains at least one primary or secondary amino group, at least one thiol group and/or at least one aromatic hydroxy group, and the polymeric carrier contains at least one hydroxy group. According to the invention the coupling is performed by forming a reactive derivative of the polymeric carrier by treatment with a sulfonyl halogenid, and reacting the formed reactive derivative with the organic ligand, which is thereby bonded directly to a carbon atom in the polymeric carrier. The polymeric carrier can, for example, be a possibly cross-linked polysaccharide, and the organic ligand is preferably a biological material such as a protein. The coupling product can, for example, be used for immunologic determinations, for affinity chromatography, etc. The coupling method can be performed under mild conditions not damaging sensitive organic ligands.